UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported):
February 2, 2011
 
 
SANGAMO BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
  
Delaware
(State or Other Jurisdiction of Incorporation)
 
 
000-30171
68-0359556
(Commission File Number)
(IRS Employer Identification No.)
   
   
501 Canal Blvd, Suite A100
Richmond, California 94804
(Address of Principal Executive Offices)
(Zip Code)
 
 
(510) 970-6000
(Registrant’s Telephone Number, Including Area Code)
 
 
 
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 2.02.  Results of Operations and Financial Condition.

          On February 2, 2011, Sangamo BioSciences, Inc. issued a press release announcing its financial results for the quarter and twelve months ended December 31, 2010.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.


Item 9.01 Financial Statements and Exhibits

(c)  Exhibits.  The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit No.
99.1                      Press Release Issued February 2, 2011.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


DATE: February 2, 2011
    
   
SANGAMO BIOSCIENCES, INC.
     
     
 
By:
/s/ EDWARD O. LANPHIER II
  
   
Edward O. Lanphier II
   
President, Chief Executive Officer